|
Aug 5
|
Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032
|
|
Aug 1
|
3 Asian Stocks Estimated To Be Up To 40.9% Below Intrinsic Value
|
|
Jul 24
|
Emerging Markets Are Trouncing U.S. Stocks. This Pro Likes Alibaba, Mercado Libre.
|
|
Jun 30
|
Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms
|
|
Jun 27
|
Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management
|
|
Jun 17
|
High Growth Tech Stocks in Asia Featuring 3 Promising Picks
|
|
Jun 16
|
/C O R R E C T I O N -- Innovent Biologics/
|
|
Jun 13
|
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions
|
|
Feb 17
|
Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer
|
|
Jan 3
|
Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration
|
|
Jan 2
|
Innovent and Roche link on lung cancer therapy development
|
|
Jan 1
|
Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate
|
|
Aug 29
|
Innovent to Present Clinical Data of Multiple Novel Molecules at WCLC and ESMO 2024
|
|
Aug 28
|
Innovent Announces 2024 Interim Results and Business Updates
|
|
Aug 28
|
High Growth Tech Stocks to Watch in Hong Kong August 2024
|
|
Aug 27
|
Exploring 3 High Growth Tech Stocks in Hong Kong
|
|
Jul 26
|
Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development
|
|
Jun 14
|
Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the 2024 ESMO Virtual Plenary
|
|
Jun 13
|
Innovent Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer
|
|
Jun 12
|
Innovent to Present Multiple Clinical Study Results of Mazdutide at the ADA's 84th Scientific Sessions
|